Impact Biomedical (IBO) Change in Receivables (2025 - 2026)

Impact Biomedical (IBO) posted Change in Receivables of -$5000.0 for Q1 2026, up 50.0% on a QoQ basis from -$10000.0 in Q4 2025.

Impact Biomedical (IBO) Change in Receivables (2025 - 2026) Analysis & Trends

Impact Biomedical's Change in Receivables history runs 2 years deep, the most recent figure standing at -$5000.0 for Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Receivables (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	75.30 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	2.84 Mn
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-39.80 Mn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-1.20 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Impact Biomedical	47.44 Mn	50.67 Mn	-	-5,000.00

Download Data